Literature DB >> 1906540

Spinal antinociception by adenosine analogs and morphine after intrathecal administration of the neurotoxins capsaicin, 6-hydroxydopamine and 5,7-dihydroxytryptamine.

J Sawynok1, A Reid, D Nance.   

Abstract

The effects of intrathecal pretreatment with the neurotoxins capsaicin, 6-hydroxydopamine and 5,7-dihydroxytryptamine on spinal antinociception by adenosine analogs (NECA, 5'-N-ethylcarboxamido adenosine and CHA, N6-cyclohexyl adenosine) and morphine were examined using the rat tail flick and hot plate tests. Pretreatment with 50 micrograms capsaicin for 7 to 11 days (which reduced substance P immunoreactivity in the superficial layers of the dorsal spinal cord) produced a slight increase in the action of NECA and CHA, and reduced the action on morphine in the hot plate test but not in the tail flick test. Pretreatment with 50 to 100 micrograms 6-hydroxydopamine for 7 to 14 days (which reduced spinal cord noradrenaline levels by 54-65%) reduced spinal antinociception by NECA and CHA but not that by morphine. Pretreatment with 50 micrograms 5,7-dihydroxytryptamine (which reduced spinal cord serotonin levels by 74-89%) had no effect on any agent. Acute pretreatment with 7.5-30 micrograms phentolamine reduced the spinal antinociceptive action of noradrenaline, NECA and CHA, primarily in the hot plate test. Phentolamine (30 micrograms) also reduced the action of morphine (hot plate greater than tail flick), but did not affect the action of L-baclofen. These results suggest that spinal antinociception by adenosine analogs: 1) occurs primarily at a postsynaptic site of action (capsaicin results), and 2) is dependent on release of endogenous noradrenaline and activation of spinal adrenergic receptors (6-hydroxydopamine and phentolamine results). The reduction in the effect of morphine by capsaicin (removes a source of adenosine release) and phentolamine (antagonizes the action of endogenously released adenosine) can be explained in terms of the adenosine release hypothesis of morphine action within the spinal cord.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1906540

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  4 in total

1.  Spinal dopaminergic projections control the transition to pathological pain plasticity via a D1/D5-mediated mechanism.

Authors:  Ji-Young V Kim; Dipti V Tillu; Tammie L Quinn; Galo L Mejia; Adia Shy; Marina N K Asiedu; Elaine Murad; Alan P Schumann; Stacie K Totsch; Robert E Sorge; Patrick W Mantyh; Gregory Dussor; Theodore J Price
Journal:  J Neurosci       Date:  2015-04-22       Impact factor: 6.167

2.  A Critical Role for Dopamine D5 Receptors in Pain Chronicity in Male Mice.

Authors:  Salim Megat; Stephanie Shiers; Jamie K Moy; Paulino Barragan-Iglesias; Grishma Pradhan; Rebecca P Seal; Gregory Dussor; Theodore J Price
Journal:  J Neurosci       Date:  2017-11-22       Impact factor: 6.167

3.  Dual allosteric modulation of opioid antinociceptive potency by α2A-adrenoceptors.

Authors:  Anne-Julie Chabot-Doré; Magali Millecamps; Lina Naso; Dominic Devost; Phan Trieu; Marjo Piltonen; Luda Diatchenko; Carolyn A Fairbanks; George L Wilcox; Terence E Hébert; Laura S Stone
Journal:  Neuropharmacology       Date:  2015-08-06       Impact factor: 5.250

4.  Chronic intrathecal morphine treatment does not cause down-regulation of spinal adenosine A1 receptors in rats.

Authors:  P L Tao; C S Wong; M C Lin
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996-07       Impact factor: 3.000

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.